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Defective hepatitis B virus (dHBV) generated from spliced RNA is detected in the sera of HBV-chronic
carriers. Our study was designed to determine whether the proportion of dHBV changed during the
course of infection, and to investigate whether dHBV might interfere with HBV replication. To achieve
this, HBV wild-type and dHBV levels were determined by Q-PCR in sera from 56 untreated chronic
patients and 23 acute patients, in sequential samples from 4 treated-patients and from liver-humanized
mice after HBV infection.
The proportion of dHBV was higher in patients with severe compared to null/moderate liver disease
or with acute infection. Follow-up showed that the proportion of dHBV increased during disease
progression. By contrast, a low and stable proportion of dHBV was observed in the humanized-mouse
model of HBV infection.
Our results highlight a regulation of the proportion of dHBV during liver disease progression that is
independent of interference with viral replication.
& 2012 Elsevier Inc. All rights reserved.Introduction
In many viral species, deletions in the genome have been
identiﬁed as leading to the generation of defective particles. These
are intrinsically non-infectious or non-replicative particles in the
absence of trans-complementation by wild-type virus (Baltimore
and Huang, 1975; Huang and Baltimore, 1970). In some cases,
defective particles may interfere speciﬁcally with the replication
of parental wild-type virus (defective interfering particles).ll rights reserved.
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ssan).Defective interfering particles have most frequently been
observed in vitro during serial passages of viruses and have been
suggested as an explanation for either the conversion from acute
in vitro infections to persistent ones, or for inﬂuencing in vivo the
course of pathogenesis (Baltimore and Huang, 1975; Holland,
1990; Huang and Baltimore, 1970; Pacini et al., 2009; Panda et al.,
2010; Scott et al., 2011; Xiao et al., 2011).
Hepatitis B virus (HBV) is a small enveloped DNA virus which is
a member of the hepadnavirus family. Its genome consists of
relaxed, circular, partially double-stranded 3.2 kb DNA (Liang,
2009). We and others have demonstrated the presence of Hepatitis
B virus (HBV) defective particles (dHBV) in serum samples from
HBV chronic carriers, as well as in the supernatant of cells
expressing the HBV genome (Cox et al., 2011; Gunther et al.,
F. Redelsperger et al. / Virology 431 (2012) 21–28221995, 1997; Preiss et al., 2008; Rosmorduc et al., 1995; Sommer
et al., 2000; Soussan et al., 2008; Terre´ et al., 1991). It was thus
demonstrated that the HBV defective particles, detected in most
serum samples from chronically infected patients (Preiss et al.,
2008; Soussan et al., 2008), were mainly generated from spliced
HBV RNAs (Gu¨nther et al., 1997; Terre´ et al., 1991). Indeed, the
3.5 kb pregenomic mRNA which is involved in HBV replication
through its reverse transcription in core particles, leading to the
secretion of infectious viral particles, may also undergo simple or
multiple splicing in the nucleus of hepatocytes (Liang, 2009;
Gu¨nther et al., 1997; Susuki et al., 1989; Terre´ et al., 1991;
Wu et al., 1991). The major spliced HBV mRNA, lacking intron
2447/489, has been described as accounting for up to 30% of
pregenomic transcripts in transfected cells and in the livers of
chronically infected patients (Susuki et al., 1989; Wu et al., 1991).
The regulation of viral splicing remains elusive, although the HBV
post-transcriptional-regulatory element (HPRE), which is involved
in the nuclear export of intron-less viral subgenomic RNAs, also
displays splicing regulatory elements that control the viral prege-
nome splicing process (Heise et al., 2006).
The quantiﬁcation of defective viral DNA remains complex in
view of the fact that apart from the deletion region, the nucleotide
sequences are identical to wild-type viral particles. In HBV, only a
small genetic region surrounding the splice donor and acceptor
sites allows speciﬁc dHBV ampliﬁcation. In two separate studies,
different quantitative PCR approaches were designed to investi-
gate the relative expression of defective HBV (dHBV) in the serum
of HBV chronic carriers, related to the severity of their liver
disease (Preiss et al., 2008; Soussan et al., 2008). We showed that
despite an expected correlation between dHBV and HBVwt viral
loads, considering that both particles derive from the same
pregenomic RNA, the proportion of circulating dHBV was higher
in patients with severe liver necrosis and ﬁbrosis (Soussan et al.,
2008). However, the other quantitative PCR approach was notHBVwt
2447
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Fig. 1. Comparison of defective HBV-DNA quantiﬁcation methods in serum from ch
represent primer locations for HBVwt ampliﬁcation (upper) and for the two different dH
overlaps both splice sites (Soussan et al., 2008), while in ampliﬁcation 2 (Preiss et al., 20
HBV chronic carriers determined by ampliﬁcation 1 or 2 and represented on a logarithm
2 obtained after comparison with 161 sequences from eight HBV genotypes (A to H) obt
patients are shown. Nucleotides R¼A/G, K¼T/G, D¼A/T/G, B¼C/T/G, Y¼C/T, S¼C/G.able to reveal the link between the proportion of dHBV and the
severity of liver disease, but suggested that antiviral resistance
mutations may enhance the relative expression of dHBV (Preiss
et al., 2008). Overall, it was clearly established by both studies
that the relative proportion of dHBV ﬂuctuated from patient to
patient (Preiss et al., 2008; Soussan et al., 2008).
The present study was designed to evaluate the relative expres-
sion of dHBV, in order to clarify the degree to which dHBV can
ﬂuctuate during the progression of liver disease. With this aim in
mind, dHBV and HBVwt genomes were quantiﬁed in serum samples
from HBV-infected patients obtained during the acute and chronic
stages of viral infection by using both our dHBV quantiﬁcation
method (Soussan et al., 2008) and that of Preiss and colleagues
(Preiss et al., 2008). We then tried to determine whether dHBV
production might interfere with HBVwt replication during the
follow-up of HBV chronic carriers by using a humanized animal
model of HBV infection.Results
Comparison of defective HBV DNA ampliﬁcation in HBV chronic
carriers
Wild-type HBV (HBVwt) DNA and defective HBV (dHBV) DNA
were quantiﬁed by real-time PCR in serum samples from 56
untreated HBV chronic carriers to evaluate the ﬂuctuation in dHBV
production. To achieve this, the dHBV DNA viral load was determined
using ampliﬁcation 1 (one primer encompassing the splice donor and
acceptor sites) (Soussan et al., 2008) and ampliﬁcation 2 (primers
surrounding the splice donor and acceptor sites) (Preiss et al., 2008)
on the same serum samples (Fig. 1A). To speciﬁcally quantify the
HBVwt viral load, one set of PCR primers was located inside the
intronic sequence and had previously been validated by comparisonINTRON
489
splicing
 AGTGTGGATTCGCACTCC 3’
Amplification 1
Reverse : 5’ CTGGTTGTTGATGATCATT 3’
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Genotype D: ------D----------D---------
Genotype E: ---------G--Y--------------
5’ CCGCGTCGCAGAAGATCT 3’
A: ----------------------------
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ronic carriers. (A) Schematic representation of HBVwt and dHBV DNAs. Arrows
BV ampliﬁcation methods (lower). Ampliﬁcation 1 uses an antisense primer which
08), primers are located around the splice sites. (B) dHBV viral load in sera from 56
ic scale. (C) Genetic variability of primer sites used for dHBV ampliﬁcation 1 and
ained from GenBank data. Only the more frequent HBV genotypes identiﬁed in our
Table 2
Clinico-pathological data of HBV acute infection (n¼23) or reactivation (n¼4)
patients.
Outcome of disease
Chronic (n¼8) Resolutive
(n¼15)
Reactivation
(n¼4)
Sex (male/female) 6/2 8/7 3/1
Age (mean in years) 35710 3579 47715
Genotypes (A/D/E) 2/3/1 2/6/3 1/1/1
Prothrombin time (%) 85714 52730 85722
HBeAg (þ/) 8/0 9/4 2/2
ALT (IU/l) 2957346 256471783 4377749
F. Redelsperger et al. / Virology 431 (2012) 21–28 23with a commercial method using an international standard panel (Pol
et al., 2008). As expected, all the samples tested were positive for
HBVwt with a mean of 1.874.1108 copies/ml and a median value
of 2.7106 copies/ml (data not shown). The comparison of both
dHBV DNA ampliﬁcations showed similar mean values (5.2106
73.6106 copies/ml with ampliﬁcation 1 and 3.110671.3
106 copies/ml with ampliﬁcation 2) and median values (1.0
105 copies/ml with ampliﬁcation 1 and 6.2105 copies/ml with
ampliﬁcation 2). A global correlation of dHBV DNA quantiﬁcation
was observed between the two methods (Pearson r2¼0.93,
po0.0001) (Fig. 1B), demonstrating their efﬁciency. When combining
both quantiﬁcation methods, dHBV DNA was detected in all the
patient samples studied with values ranging from 800 to
2108 copies/ml, and as previously reported, the quantity depended
on the level of HBVwt (Preiss et al., 2008; Soussan et al., 2008).
However, in 17% of the patients studied (10/56), an absence of dHBV
DNA ampliﬁcation was observed with one of the two used methods.
This difference may have been due to the primer design, which was
limited by the need to recognize DNA around or overlapping the
splice sites in dHBV-DNA without any interference of HBVwt DNA.
Indeed, as illustrated in Fig. 1C, viral genetic variability, evaluated
from GenBank whole HBV sequences (n¼161) and represented as a
function of different genotypes, was observed in the primers used to
quantify dHBV (with both methods). However, in 15 sequenced HBV
samples of our cohort, genetic variability (ranging from 0 to 3 nucleo-
tides) was only observed in the reverse primer sequences used for
each ampliﬁcation method. To investigate the impact of these
mismatches on dHBV quantiﬁcation, we reanalysed the dHBV viral
loads using three additional reverse primers on these samples (see
Tables 1 and 2 in the supplementary data). Apart from samples where
dHBV DNA could not be detected with one of themethods, the results
showed the correlation of viral loads previously observed. Never-
theless, the possible absence of dHBV DNA ampliﬁcation incited us to
ensure the systematic use of both PCR methods during later
experiments.Defective HBV DNA at different stages of viral liver disease
in HBV-infected patients
In order to investigate the relationship between the relative
dHBV expression level and liver disease independently of viral
replication, the proportion of dHBV to total HBV (dþwt) DNA was
compared with ALT levels and the Metavir score. The proportion
of dHBV varied independently of the ALT level in chronic carriers.
(Fig. 2A). Conversely, the mean proportion of dHBV was higher in
severe liver disease (9.773.1%, 6.372.0% with ampliﬁcations 1Table 1
Clinico-pathological data of HBV chronic patients (n¼56) according to liver
disease.
Liver disease
Null/moderate (n¼28) Severe (n¼28)
Sex (male/female) 15/13 28/0
Age (mean in years) 29.778.8 38.8712.8
ALT (IU/L) 73754 1187106
Genotypes (A/C/D/E) 10/8/2/7 13/4/4/7
HBeAg (þ /) 21/7 12/12
Metavir score A1F1: 18 (64%) A3F4: 11 (40%)
A2F1: 5 (17%) A2F4: 5 (17%)
A0F1: 4 (14%) A1F4: 4 (14%)
A0F2: 1 (4%) A3F3: 4 (14%)
A1F3: 2 (7%)
A2F3: 2 (7%)and 2, respectively) than in null/moderate liver disease as
classiﬁed by the Metavir scores (1.670.5%, 1.970.5% for ampli-
ﬁcations 1 and 2, respectively) (Fig. 2B), and the difference was
statistically signiﬁcant using both dHBV-DNA quantiﬁcations
(p¼0.01 and 0.04). In chronic patients, ALT levels are generally
insufﬁcient to determine disease severity, so Metavir scores are
more classically employed. Our results conﬁrmed that circulating
dHBV particles were enriched (proportionally to HBVwt) in serum
samples from patients with severe rather than moderate liver
disease. In order to reduce the inﬂuence of genetic variability
on dHBV DNA quantiﬁcation, patients with an undetectable
dHBV viral load using one of the two methods of dHBV ampliﬁca-
tion were removed from the calculations. The mean proportion of
dHBV remained higher in severe disease (11.373.5%, 6.572.0%
with ampliﬁcations 1 and 2, respectively) than in null/moderate
liver disease (2.170.6%, 1.970.5% for ampliﬁcations 1 and 2,
respectively) (p¼0.01 and 0.03), thus conﬁrming our ﬁndings.
Finally, our results were in favor of a regulation of dHBV levels
as a function of severity of liver disease. We therefore investi-
gated the proportion of dHBV in sera from untreated patients
with acute HBV infection (viral load 4105 copies/ml, n¼23)
or with HBV reactivation (n¼4), who were all highly positive
for IgM anti-HBc. As expected, the HBVwt viral load (mean:
1.410971.1109 copies/ml; median: 7.3106 copies/ml) and
ALT levels were higher in acute patients than in those observed
during chronic infection (Table 2). Despite the increase in viral
load and cytolysis, the proportion of dHBV during acute infection
(3.272.6%, 0.770.5% with ampliﬁcations 1 and 2, respectively)
was signiﬁcantly lower rather than moderate (p¼0.04 and 0.03,
using dHBV ampliﬁcations 1 and 2), or severe (po0.001 using
dHBV ampliﬁcation 1 or 2) chronic liver disease (Fig. 2B). Indeed,
only 2 out of 23 patients (8%) had a dHBV ratio higher than 1%
during acute infection, compared with 10/28 (35%) and 18/28
(64%) of patients with moderate and severe liver disease, respec-
tively. Furthermore, the higher proportion of dHBV, observed in
the two acutely infected patients, was not associated with the
outcome of viral infection. Indeed, the infection resolved in one of
them (1/15), while the other progressed to chronic infection (1/8).
Additionally, during an exacerbation of either chronic (n¼2) or
occult (n¼2) HBV infection, the proportion of dHBV remained
lower than 0.1% using both dHBV DNA ampliﬁcation techniques.
Taken together, these results suggest that the proportion of dHBV
is related to liver status in chronic patients and is independent of
liver cytolysis (ALT level) in chronic and acute patients.
Defective HBV DNA during liver disease progression
In order to investigate whether the proportion of dHBV might
be modulated during the course of liver disease, we retrospec-
tively analyzed the dHBV and HBVwt viral loads in sequential
serum samples obtained from four, treated chronic HBV carriers
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Fig. 2. Proportion of dHBV in acute and chronic stages of HBV infection. (A) The proportion of defective particles (%) was expressed in sera from patients with HBV chronic
hepatitis and plotted against the ALT levels using ampliﬁcation 1 (left panel) or 2 (right panel). (B) The proportion of defective particles (%) obtained using ampliﬁcation 1
(left panel) or 2 (right panel) was represented in patients classiﬁed as HBV acute, null or moderate and severe liver disease. *¼p value calculated with Mann–Whitney.
F. Redelsperger et al. / Virology 431 (2012) 21–2824over follow-up periods ranging from 9 to 16 years (Fig. 3).
As illustrated, the amounts of both HBVwt and dHBV DNAs in these
sera decreased following antiviral therapy (indicated by arrows
and letters). In accordance with our previous data, the dHBV viral
load was only detectable when the HBVwt viral load was higher
than 103 copies/ml (Soussan et al., 2008). As illustrated in Fig. 3,
antiviral therapy affected both the HBVwt and dHBV viral loads.
Furthermore, the emergence of antiviral resistance mutations in
patients 1 and 3 (appearance of M204Vpol with lamivudin-resis-
tance) did not impact dHBV synthesis (Fig. 3). Follow-up showed
that the dHBV levels were very low and constant during non-
progressing liver disease (patients 1 and 2). By contrast, in patients
3 and 4, the proportion of dHBV varied during the course of
infection, ranging from 1% to 60% of total viral circulating particles.
These ﬂuctuations were only observed in patients progressing to
severe disease, as illustrated by their ALT levels and/or Metavir
scores. This was seen in the absence of an effective therapy and
genetic variability in primer regions used for dHBV DNA ampliﬁca-
tion during follow-up. In conclusion, a variation of the proportion
of dHBV from 1% to 60% in the same patient raised the question of
possible viral interference of dHBV with viral replication.
Defective HBV DNA secretion in humanized Alb-uPA/SCID mice
infected by HBV
The uPA transgenic mouse model with humanized liver was
used to investigate the production of dHBV DNA after infectionand to test whether dHBV might interfere with HBVwt replication.
For this purpose, human hepatocytes were transplanted into uPA
homozygous mice and infected with an inoculum of HBV
obtained from HepG2.2.15 cells. This mouse model closely
mimics HBV infection in human patients (Dandri et al., 2001;
Morosan et al., 2006; Brezillon et al., 2011).
We ﬁrst of all evaluated the proportion of dHBV in the viral
inoculum obtained from the HepG2.2.15 cell supernatant which
was used to infect the humanized mice. This was found to be
small (0.05%), despite high levels of HBVwt (5.81010 copies/ml)
and dHBV (2.7107 copies/ml) (Fig. 4A). By contrast, Northern
blot analysis using an HBV capsid probe (to reveal both prege-
nomic and spliced viral RNAs), showed that the 2.2 Kb spliced
RNA corresponded to 15% of total pregenomic RNAs in
HepG2.2.15 cells, and an HBV full length probe was used as a
control to reveal pregenomic and subgenomic envelope RNAs
(Fig. 4B).
After the intraperitoneal injection of 109 HBV genomes equiva-
lent, viral replication was investigated in sequential serum
samples from 7 to 103 days post-infection in three humanized
mice (Figs. 4C). In all mice, we observed a delay in the detection of
dHBV DNA which ranged from 10 to 66 days post-infection when
the HBVwt viral load reached about 10
6 copies/ml. Subsequently,
the dHBV viral load varied as a function of the HBVwt viral load.
When detectable, the proportion of dHBV was very small, ranging
from 0.06% to 0.6% throughout follow-up of the three mice
studied. In addition, liver RNAs were studied using RT-PCR and
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F. Redelsperger et al. / Virology 431 (2012) 21–28 25RT Q-PCR analysis (Fig. 4C). As expected, end point RT-PCR using
primers located on either side of the splice sites only enabled the
detection of 2.2 Kb spliced RNA (350 bp) and not pregenomic RNA
(1550 bp). In fact, RT Q-PCR analysis showed that 2.2 Kb spliced
RNA represented only 1.3% of total liver pregenomic RNAs, a levelcomparable to the proportion (0.5%) obtained in the related time
point serum sample. Taken together, our data showed that the
relative proportion of dHBV remained constant in this model,
suggesting an absence of dHBV viral interference on HBV
replication.
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controls. Left panel: quantiﬁcation of defective and wild-type viral RNAs (copies/mg RNA) by RT Q-PCR in the liver of the mouse followed for 30 days.
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To date, the relationship between the proportion of HBV defective
particles and liver disease has remained controversial (Preiss et al.,
2008; Soussan et al., 2008). Thus, using the two previously published
dHBV quantiﬁcation methods on the same serum samples, we ﬁrst of
all conﬁrmed the detection of a higher proportion of dHBV in patients
with severe versus moderate chronic liver disease. We then showed
that the proportion of dHBV was signiﬁcantly lower in acute versus
chronic infected patients, despite a higher level of viral replication. In
addition, we conﬁrmed that ALT levels were not related to a
modulation in the proportion of defective particles. Finally, we
observed that the proportion of dHBV could ﬂuctuate during the
course of liver disease in a given patient. Taken together, our ﬁndings
were in favor of regulation of the proportion of dHBV that is
dependent on liver status during HBV infection.Several hypotheses might account for ﬂuctuations in the
proportion of dHBV during viral disease. One is the behavior of
dHBV particles when they act as defective interfering particles on
HBV replication. We therefore tested this hypothesis in a huma-
nized mouse model of HBV infection and found that dHBV was
not detected during the primary phase of the infection and the
proportion remained low (o1%) and constant after establishment
of the infection. In the absence of immune-mediated viral
pathology in the liver of these transgenic mice, the proportion
of dHBV remained stable. By contrast, the proportion of dHBV
varied signiﬁcantly in serum samples from patients with severe
liver disease when compared to sera obtained during other stages
of HBV infection. These ﬁndings point towards an absence of
dHBV interference with HBV replication and suggest that another
mechanism may be involved in regulating the proportion
of dHBV.
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supernatant was 300-fold lower than the intracellular proportion
of spliced forms. The difference between intra- and extra-cyto-
plasmic dHBV genomes had previously been reported in transient
HBV transfection and a defect in the secretion or viral maturation
of dHBV particles explained these results in liver carcinoma cells
(Abraham et al., 2008; Sommer et al., 2000). By contrast, this
proportion was comparable in serum and humanized mouse liver.
However, until now, the difference between intra- and extracel-
lular proportions of dHBV has not been veriﬁed in HBV-infected
patients and needs to be investigated as a function of liver status,
during future studies.
Regulation of the alternate splicing event may also be involved
in the differential proportions of dHBV observed in patients.
Indeed, mutations of cis-acting elements (splice sites, enhancer
and silencer regions) or the abnormal expression/phosphorylation
of trans-acting factors (SR and hnRNP proteins) have been
reported during human diseases, including liver cirrhosis
(Grosso et al., 2008; Sommer et al., 2000; Wang and Cooper,
2007). The HBV genome displays various potential splicing
regulation sites (HPRE, splice donor and acceptor sites, etc.)
(Sommer and Heise, 2008). However, sequence analysis of HBV
in chronic carriers during a longitudinal study revealed a high
level of nucleotide sequence conservation in both splice donor
and acceptor sites, as well as in the HPRE region (data not shown).
In addition, alterations to the expression of splicing factors have
been described in aberrantly spliced genes during human patho-
genesis (Grosso et al., 2008). An example in human cancers is the
over-expression of ASF/SF2, a trans-acting splicing factor, which
leads to the synthesis of an oncogenic isoform of the ribosomal
protein S6 kinase-b1, or the RON splice variant (Cooper et al.,
2009; Karni et al., 2007). It could be hypothesized that splicing
factor expression may modulate HBV alternate splicing in severe
liver disease and thus explain the rise in the proportion of dHBV.
However, until now, we did not know which regulatory proteins
controlled the alternate splicing of HBV pregenomic RNA,
although the over-expression of PTB-associated-splicing-factor
has been described in vitro as slightly enhancing viral splicing
(Sommer and Heise, 2008). Further studies are necessary to better
understand the mechanisms involved in the alternate splicing of
HBV pregenomic RNA.
Our results conﬁrmed the increase in the proportion of dHBV
in patients with severe liver disease and highlighted a regulation
of dHBV expression during the progression of liver disease. The
regulation of dHBV expression may therefore induce either a
modulation of viral protein expression or the appearance of
splice-speciﬁc viral proteins. Indeed, we have shown that HBV
singly-spliced RNA, and its related dHBV DNA, generate expres-
sion of the spliced protein, HBSP, and also induce an over-
expression of HBc antigen (Lu et al., 2006; Rosmorduc et al.,
1995, 1999; Soussan et al., 2000, 2003). The role of HBSP during
liver disease remains elusive; however, its expression has been
shown to induce an immune response and modulate cell viability
(Lu et al., 2006; Mancini-Bourgine et al., 2007; Soussan et al.,
2000). In summary, our results show that the progression of HBV
liver disease leads to an increase in the proportion of dHBV
without there being any viral interference with HBV replication.Patients and methods
Subjects
Fifty-six chronic HBV carriers, with an HBV viral load
4105 copies/ml but no marker for HCV or HDV, and who had
never received HBV antiviral therapy, were included in our study.Liver biopsies were classiﬁed using the Metavir scoring method.
Moderate (n¼28) or severe (n¼28) liver disease was classiﬁed
according to the Metavir score, and alanine amino transferase
activity (ALT) and the presence of HBeAg were determined using
standard assays (BioMerieux) (Table 1).
Twenty-three acute and four reactivation HBV patients posi-
tive for HBsAg and IgM anti-HBc, with an HBV viral load
4105 copies/ml were included retrospectively. The course of
these patients towards chronic (n¼8) or resolving infection
(n¼15) was known. Acute hepatitis was characterized by ALT
levels and the prothombin time, and HBV by genotype, HBeAg and
viral load. HBV reactivation was observed in occult hepatitis
(n¼2) or chronic infected (n¼2) patients. Clinical and pathologi-
cal data concerning these patients are summarized in Table 2.
Sequential retrospective serum samples obtained from four
additional chronic treated carriers followed for period ranging
from 9 to 16 years were also studied.
All samples obtained from clinical units in Paris Public Hospi-
tals (AP-HP) with an agreement of the local Ethics Committee, and
written informed consent was obtained from all the patients
(in accordance with Article L-1245-2 of the French Huriet Law).
PCR and real-time PCR
The two approaches used to quantify dHBV-DNA involved
primers located either within (ampliﬁcation 1, reverse-primer)
or encompassing (ampliﬁcation 2) the splice sites (Preiss et al.,
2008; Soussan et al., 2008) (Fig. 1C). Viral DNA was extracted
from the sera (200 ml) using a spin column (Qiagen) and then
eluted in 200 ml water. Real-time quantitative PCR (Q-PCR) used
either the LightCycler System (Roche) (ampliﬁcation 1) or the
7500 Taqman System (AppliedBiosystem) (ampliﬁcation 2), as
described elsewhere (Preiss et al., 2008; Soussan et al., 2008).
All PCR quantiﬁcations were performed using SYBR green labeling.
The threshold value was deﬁned (500 copies/ml) for each Q-PCR.
To take account of patients with undetectable viral loads when
calculating dHBV proportions, an arbitrary value of 1 copy/ml was
attributed.
Cell culture and HBV analysis
The human HepG2.2.15 cell line stably expressing HBV was
grown in William’s medium supplemented with 10% FCS and
antibiotics. Cell supernatants were collected and HBV was con-
centrated according to the method described in previous reports
(Hantz et al., 2009). HBV RNAs from HepG2.2.15 or liver cells
were extracted using the RNeasysMini Kit (Qiagen), according to
the manufacturer’s recommendations. Northern blot analysis was
performed as previously described (Soussan et al., 2000) using
HBV capsid (to detect pregenomic and 2.2 Kb spliced RNAs) and
whole HBV genome (for pregenomic and subgenomic RNAs)
probes. Quantitative and end point PCR were performed on liver
RNAs after reverse transcription using superscript enzyme and
random primers, according to the manufacturer’s recommenda-
tions. End point PCR was performed in order to amplify both the
dHBV and HBVwt genomes with the same couple of primers using
a method previously described (Soussan et al., 2000).
Transplantation of human hepatocytes and HBV infection
The generation of Alb-uPA/RAG mice has been described else-
where (Dandri et al., 2001; Morosan et al., 2006; Brezillon et al.,
2011). Primary human hepatocytes were obtained in a cryopre-
served state (Biopredic International, France). Preparations with
at least 80% cell viability were transplanted (8105) into the
spleen of 16–20-day-old uPAþ /þ/Rag2/ mice (Dandri et al.,
F. Redelsperger et al. / Virology 431 (2012) 21–28282001; Morosan et al., 2006; Brezillon et al., 2011). The levels of
human albumin in sera were quantiﬁed by ELISA, according to
the manufacturer’s instructions (Bethyl Laboratories). HBV was
concentrated from supernatants of the HepG2.2.15 line stably
expressing HBV (Hantz et al., 2009). The viral preparation
was suspended in Williams’s medium at a concentration of
11010 genome equivalents/ml. Four to ﬁve weeks after trans-
plantation, animals with a level of human albumin secretion of at
least 100 mg/ml were infected with 1109 HBV genome equiva-
lents by intraperitoneal injection. At the indicated time post-
infection, HBV DNA was extracted from 20 ml of mouse sera as
indicated by the manufacturer (Qiablood extraction kit, Qiagen,
Courtaboeuf, France).
Statistical analysis
Statistical analysis was performed using Mann–Whitney non-
parametric tests. The correlation assay was evaluated by the
Spearman Rank test (GraphPad Prism 5). A p value o0.05 was
considered as signiﬁcant.Acknowledgments
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